- Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
- Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
- Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
- Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
- Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
More ▼
Key statistics
On Friday, Coherus BioSciences Inc (CHRS:NMQ) closed at 1.82, 27.26% above the 52 week low of 1.43 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.90 |
---|---|
High | 1.93 |
Low | 1.81 |
Bid | 1.80 |
Offer | 1.85 |
Previous close | 1.88 |
Average volume | 1.37m |
---|---|
Shares outstanding | 114.73m |
Free float | 110.09m |
P/E (TTM) | -- |
Market cap | 239.78m USD |
EPS (TTM) | -0.7801 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼